L3VLUP
ProSign in

IONS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IONSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IONS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterIONSVRTX
Q3 202015 holders, $2.1bn31 holders, $21.9bn
Q4 202014 holders, $2.5bn30 holders, $18.4bn
Q1 20219 holders, $1.9bn31 holders, $15.4bn
Q2 202110 holders, $1.8bn30 holders, $12.7bn
Q3 20218 holders, $1.4bn35 holders, $10.1bn
Q4 20219 holders, $1.3bn28 holders, $12.4bn
Q1 20229 holders, $1.6bn23 holders, $16.1bn
Q2 202212 holders, $1.6bn25 holders, $18.1bn
Q3 202211 holders, $1.5bn22 holders, $18.4bn
Q4 20229 holders, $1.2bn28 holders, $18.4bn
Q1 20237 holders, $1.0bn26 holders, $21.4bn
Q2 202310 holders, $1.3bn27 holders, $24.7bn
Q3 202312 holders, $1.4bn33 holders, $24.3bn
Q4 202314 holders, $1.9bn32 holders, $28.6bn
Q1 202415 holders, $1.7bn31 holders, $29.8bn
Q2 202417 holders, $2.1bn29 holders, $33.4bn
Q3 202416 holders, $2.1bn27 holders, $33.5bn
Q4 202411 holders, $1.7bn26 holders, $28.5bn
Q1 202510 holders, $1.5bn21 holders, $35.4bn
Q2 202513 holders, $2.1bn21 holders, $32.3bn
Q3 202518 holders, $3.6bn22 holders, $25.9bn
Q4 202515 holders, $4.9bn26 holders, $31.8bn
Q1 202616 holders, $5.0bn25 holders, $31.8bn
Q2 202613 holders, $5.5bn26 holders, $34.6bn
IONS

Ionis Pharmaceuticals Inc

Holders
14
Reported value
$1.9bn
Buyers
10
Sellers
4

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IONS (4)

Baillie Gifford & Co, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Verition Fund Management LLC

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →